Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Luke who wrote (636)	11/17/2001 8:26:37 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1833

Yeah, and Drs. Behan and Chalmers were key players in the CRF/Urocortin program. It would be great to know the story of why they left. >> Arena just seemed like a more than fair price in the same area. << Like I said, I haven't looked at them. I should have, given the heavyweight MPM support. But, we (Tomato and me) were talking 3X capitalization, and I thought that you were implying that the same sort of premium might go to cash-rich-but-not-discounted-to-cash ARNA. To that, I said "no". I wasn't implying that it wasn't under valued. >> I am not familiar enough what KDUS technology went to Axiom. << None that I know of..... KDUS owns a large chunk of Axiom. I've lost track of the exact size, as there was an equity deal with Biacore and then Axiom later converted a Biacore license to exclusive and got a large part of their shares back. Maybe BM has an estimate? >> I was wondering what the overall added value/necessity is of the yeast screen to someone doing GPCR screens. << OSIP made it sound like it was jelly to peanut butter. They absolutely raved about their system and how they got it cheap. Sounded like it was a marriage in heaven, and then....... wham!...... OSIP reorganizes R&D and Dr. Webb's name isn't mentioned. Left me going "huh?", and I'm still going "huh?". It would help to know if Webb was negotiating the Syrrx deal before the shakeup at OSIP.